{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/31",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.025,
        "w": 0.068,
        "x": 0.038,
        "y": 0.93
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "991baed7-db71-47aa-8480-d49cdfe5e604",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.56,
        "w": 0.916,
        "x": 0.046,
        "y": 0.242
      },
      "kind": "list",
      "text": "DR is one of the largest markets in retina with 10M patients in US and over 100M worldwide\nMajority of the NPDR patients are not candidates for approved biologics treatments and are left untreated\nAPX3330 first-in-class oral drug with unique MOA that inhibits Ref-1 which reduces VEGF and inflammatory cytokines to normal physiological levels\nPrevention of worsening is a clinically meaningful potential registration endpoint\nAPX3330 demonstrated favorable safety and tolerability in diabetic patients\nSuccessful EOP2 meeting with the FDA and a Special Protocol Assessment (SPA) to be submitted\nAPX3330 has the potential to be an early, non-invasive preventative treatment for the 8 million NPDR patients with the potential to treat other organs affected by diabetes (e.g., kidney disease, peripheral neuropathy)\nBroad prescriber base including general ophthalmology, optometry and primary care due to favorable safety",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0622e6d-5ebf-42b2-86b4-e7558ab3b544",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.018,
        "x": 0.953,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "31",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "152dfd59-1442-44b1-8469-ac7ff83795e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.54,
        "x": 0.046,
        "y": 0.06
      },
      "kind": "title",
      "text": "DR and APX3330 Key Takeaways",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f0d5ca8-bafa-4c89-81f1-0d63afc951b4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f721b647-3b3c-47ca-bb0a-173e784e8dd9",
      "evidence": "list/bullet: DR is one of the largest markets in retina with 10M patients in US and over 100M worldwide",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 29,
      "beatId": "691510f1-c63c-46db-bda1-6d94434f6f9b",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 29-42 discuss key takeaways, corporate highlights, and future plans",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 31,
      "from": 30,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "73d97d04-557b-44ca-a1d1-9e0d6b27f716",
      "evidence": "Slides 30-31 summarize APX3330's benefits and key takeaways",
      "position": 1,
      "objective": "Why APX3330 is a good solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}